Free tool
Drug Trial Radar
Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
53
Recruiting, any sponsor type, condition "HIV-1"
By trial status
The same filters, counted in each status. Pick one to switch.
- Completed1,274
53 trials
Showing 1 to 25, recently updated first.
- A Clinical Trial to Look at the Safety and Immune Responses of the RNA-based Vaccine BNT168 in Adults Living With or Without HIVPivotal-lookingRecruiting
BioNTech SEIndustry
NCT07698600 · 126 participants (planned) · Start Aug 4, 2026 · Primary completion Feb 2028
Drug: BNT168 · For: HIV -1 Infection
Sites: St Louis, Missouri; Knoxville, Tennessee; Houston, Texas · 6 sites in all
ANRS, Emerging Infectious DiseasesGovernment (non-federal)
NCT05300035 · 69 participants (planned) · Start Apr 11, 2024 · Primary completion Dec 10, 2026
Drug: Recombinant human monoclonal antibody (bNAbs); Placebo · For: HIV/AIDS and Infections
Sites: Bobigny, France; Clamart, France; Clichy, France · 17 sites in all
- Study of Lenacapavir, Teropavimab, and Zinlirvimab Versus Cabotegravir and Rilpivirine in Virologically Suppressed Adults With HIV-1 on Oral Daily Antiretroviral TherapyPivotal-lookingRecruiting
Gilead SciencesGilead Sciences (GILD)
NCT07682961 · 850 participants (planned) · Start Jul 14, 2026 · Primary completion Mar 2029
Drug: Lenacapavir; Lenacapavir Tablet and 4 more · For: HIV Infections
Sites: Bakersfield, California; Beverly Hills, California; Hidden Valley Lake, California · 61 sites in all
National Institute of Allergy and Infectious Diseases (NIAID)NIH
NCT07390955 · 83 participants (planned) · Start Mar 19, 2026 · Primary completion Aug 30, 2027
Drug: ePGT121v1-LS (IV); PGDM1400LS (IV) and 4 more · For: HIV
Sites: Birmingham, Alabama; San Francisco, California; Atlanta, Georgia · 11 sites in all
- bNAbs and Anti-PD-1 in HIVRecruiting
Ole Schmeltz SøgaardAcademic, hospital or other
NCT07820813 · 90 participants (planned) · Start Oct 7, 2026 · Primary completion Sep 15, 2029
Drug: 3BNC117-LS; 10-1074-LS and 1 more · For: HIV-1
Sites: Aarhus, Denmark
CAN Community HealthAcademic, hospital or other
NCT07476339 · 200 participants (planned) · Start Jun 17, 2026 · Primary completion Jun 17, 2027
Drug: Bictegravir, emtricitabine, and tenofovir alafenamide · For: HIV -1 Infection; HIV (Human Immunodeficiency Virus); HIV and 1 more
Sites: Clearwater, Florida; Ft. Pierce, Florida; Jacksonville, Florida · 11 sites in all
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT07850609 · 80 participants (planned) · Start Oct 27, 2026 · Primary completion Dec 2, 2027
Drug: Alimatravir · For: HIV
Sites: San Francisco, California; Washington D.C., District of Columbia; Boston, Massachusetts · 7 sites in all
- A Phase 2b Study Evaluating Oral VH4524184 Regimens in Treatment Naïve Persons With HIV-1 (INNOVATE Study)Pivotal-lookingRecruiting
ViiV HealthcareGSK (GSK)
NCT07202546 · 186 participants (planned) · Start Feb 11, 2026 · Primary completion Oct 28, 2027
Drug: VH4524184; Emtricitabine (FTC) and tenofovir alafenamide (TAF) Fixed Dose Combination (FDC) tablets and 1 more · For: HIV Infections
Sites: Bakersfield, California; Palm Springs, California; West Hollywood, California · 125 sites in all
- A Study of GS-3242 in Combination With Lenacapavir Versus Biktarvy in Virologically Suppressed People With HIV-1Pivotal-lookingRecruiting
Gilead SciencesGilead Sciences (GILD)
NCT07645287 · 175 participants (planned) · Start Jun 15, 2026 · Primary completion Aug 2027
Drug: GS-3242 Tablet; GS-3242 Injection and 3 more · For: HIV-1-infection
Sites: Phoenix, Arizona; Beverly Hills, California; Los Angeles, California · 59 sites in all
- Study of an Injectable Regimen of GS-3242 With Lenacapavir Compared to Biktarvy in People New to HIV-1 TreatmentPivotal-lookingRecruiting
Gilead SciencesGilead Sciences (GILD)
NCT07708727 · 700 participants (planned) · Start Jul 29, 2026 · Primary completion Oct 2030
Drug: GS-3242 Tablet; GS-3242 Injection and 3 more · For: HIV-1-infection
Sites: Torrance, California; New Haven, Connecticut; Ft. Pierce, Florida · 21 sites in all
Gilead SciencesGilead Sciences (GILD)
NCT06337032 · 350 participants (planned) · Start Aug 27, 2024 · Primary completion Jun 2027
Drug: F/TAF (High Dose Tablet); F/TAF (Low Dose Tablet) and 19 more · For: HIV-1-infection
Sites: Buenos Aires, Argentina; Panama City, Panama; Cape Town, South Africa · 17 sites in all
- A Clinical Study of Islatravir and Ulonivirine for People With HIV-1 Who Have Not Been Treated Before (MK-8591B-062)Pivotal-lookingRecruiting
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT07266831 · 570 participants (planned) · Start Dec 18, 2025 · Primary completion Feb 1, 2029
Drug: ISL; ULO and 4 more · For: Human Immunodeficiency Virus Type 1 (HIV-1) Infection
Sites: Los Angeles, California; Denver, Colorado; Washington D.C., District of Columbia · 56 sites in all
National Institute of Allergy and Infectious Diseases (NIAID)NIH
NCT06517693 · 48 participants (planned) · Start Jan 5, 2026 · Primary completion Nov 30, 2027
Drug: PGT121.414.LS; VRC07-523LS · For: HIV-1
Sites: Los Angeles, California; Aurora, Colorado; Jacksonville, Florida · 19 sites in all
International Maternal Pediatric Adolescent AIDS Clinical Trials GroupResearch network
NCT07637942 · 40 participants (planned) · Start Oct 1, 2026 · Primary completion Apr 22, 2028
Drug: Every 4-week long-acting injectable cabotegravir and rilpivirine; Every 4-week long-acting injectable cabotegravir and rilpivirine · For: HIV -1 Infection
Sites: La Jolla, California; Los Angeles, California; Aurora, Colorado · 10 sites in all
- Evaluating the Safety and Immunogenicity of MTBVACPivotal-lookingRecruiting
HIV Vaccine Trials NetworkResearch network
NCT05947890 · 276 participants (planned) · Start Jan 30, 2024 · Primary completion Nov 2027
Drug: MTBVAC; BCG · For: HIV I Infection; Tuberculosis
Sites: Johannesburg, South Africa; Westdene, South Africa; Durban, South Africa · 16 sites in all
- Dasatinib for HIV-1 Reservoir ReductionRecruiting
National Institute of Allergy and Infectious Diseases (NIAID)NIH
NCT07342491 · 14 participants (planned) · Start May 8, 2026 · Primary completion Apr 9, 2027
Drug: Dasatinib · For: HIV Infections
Sites: Chicago, Illinois; Cleveland, Ohio; Seattle, Washington
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT04375800 · 84 participants (planned) · Start Feb 3, 2021 · Primary completion Nov 12, 2028
Drug: Doravirine; 2 NRTIs and 1 more · For: Human Immunodeficiency Virus (HIV) Infection
Sites: Aurora, Colorado; Atlanta, Georgia; Rionegro, Colombia · 26 sites in all
- Substudy-01: A Study of Long-Acting HIV-1 Treatments Taken by Mouth in People With HIV-1 With Undetectable Virus LevelsPivotal-lookingRecruiting
Gilead SciencesGilead Sciences (GILD)
NCT07841990 · 125 participants (planned) · Start Oct 1, 2026 · Primary completion Aug 2027
Drug: B/F/TAF; GS-3242 and 1 more · For: HIV-1 Infection
Sites: Ft. Pierce, Florida; Houston, Texas
- A Study of MK-8527 to Prevent Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8527-010)Pivotal-lookingRecruiting
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT07071623 · 4,580 participants (planned) · Start Nov 10, 2025 · Primary completion Oct 18, 2027
Drug: MK-8527; Emtricitabine/tenofovir disoproxil (FTC/TDF) and 2 more · For: Human Immunodeficiency Virus (HIV); HIV Pre-Exposure Prophylaxis
Sites: Homabay County, Kenya; Thika, Kenya; Nairobi, Kenya · 30 sites in all
- Safety Study of MucoCept-CVNRecruiting
Craig Cohen, MD, MPHAcademic, hospital or other
NCT07181486 · 12 participants (planned) · Start Oct 6, 2025 · Primary completion Apr 30, 2027
Drug: Live Biotherapeutic Product L. jensenii 1153-1666; Placebo · For: HIV -1 Infection
Sites: San Francisco, California
Fundación HuéspedAcademic, hospital or other
NCT07357584 · 100 participants (planned) · Start Sep 16, 2026 · Primary completion Apr 30, 2028
Drug: Doravirine / lamivudine/ Tenofovir Disoproxil Oral Tablet · For: HIV-1-infection
Sites: Ciudad Autonoma de Buenos Aire, Argentina; Buenos Aires, Argentina
- Study of GS-0415 and How It Works in People With HIVPivotal-lookingRecruiting
Gilead SciencesGilead Sciences (GILD)
NCT07719491 · 112 participants (planned) · Start Jul 22, 2026 · Primary completion Aug 2029
Drug: GS-0415; GS-0415 Placebo · For: HIV -1 Infection
Sites: Los Angeles, California; Washington D.C., District of Columbia; Miami Lakes, Florida · 16 sites in all
- Dolutegravir/Lamivudine in Treatment-Naïve Pregnant WomenPivotal-lookingRecruiting
Fundación HuéspedAcademic, hospital or other
NCT07616739 · 210 participants (planned) · Start Sep 10, 2026 · Primary completion Oct 15, 2028
Drug: Dolutegravir/Lamivudine 50 MG-300 MG Oral Tablet [DOVATO]; TDF/XTC or TAF/FTC plus Dolutegravir (XTC stand for lamivudine OR emtricitabine) · For: HIV-1-infection
Sites: Ciudad Autónoma de Buenos Aires, Argentina; El Palomar, Argentina; Isidro Casanova, Argentina · 10 sites in all
University of AarhusAcademic, hospital or other
NCT05668026 · 18 participants (planned) · Start Apr 1, 2024 · Primary completion Mar 1, 2027
Drug: Venetoclax · For: HIV-1-infection
Sites: Melbourne, Australia; Aarhus, Denmark
BioNTech SEIndustry
NCT07392372 · 67 participants (planned) · Start Feb 9, 2026 · Primary completion Nov 2026
Drug: BNT351; Placebo and 2 more · For: HIV -1 Infection
Sites: Chicago, Illinois; Baltimore, Maryland; St Louis, Missouri · 6 sites in all
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.